Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
13.38
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Apr 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
200
Open
13.38
Bid (Size)
13.19 (11)
Ask (Size)
13.40 (2)
Prev. Close
13.38
Today's Range
13.38 - 13.38
52wk Range
13.11 - 17.11
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
April 23, 2024
Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement in MADRS scores. William Blair sees the potential for $1 billion+ in...
Via
Benzinga
No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win
April 23, 2024
The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza.
Via
Investor's Business Daily
Performance
YTD
-6.69%
-6.69%
1 Month
-5.44%
-5.44%
3 Month
-9.16%
-9.16%
6 Month
-8.23%
-8.23%
1 Year
-20.64%
-20.64%
More News
Read More
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
April 18, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
April 08, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
March 26, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
March 26, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
March 19, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
March 19, 2024
From
Centogene NV
Via
GlobeNewswire
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
March 13, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
The Hot List: 3 AI Stocks Worth Buying on Weakness
March 01, 2024
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
February 26, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
FDA Approves Takeda's Eohilia As First Oral Treatment For Inflammed Esophagus
February 12, 2024
Via
Benzinga
Exposures
Product Safety
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
February 12, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Good News For Sleep Disorder Patients - Takeda's Therapy Shows Promise In Mid-Stage Study
February 09, 2024
Via
Benzinga
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
February 08, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Why Is Japanese Drugmaker Takeda Stock Trading Lower Today?
February 01, 2024
Via
Benzinga
Takeda Announces Chief Financial Officer Succession
February 01, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Earnings Scheduled For February 1, 2024
February 01, 2024
Via
Benzinga
Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products
February 01, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
January 29, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
January 29, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
3 Stocks to Buy to Benefit From the Booming Sleep Industry
January 23, 2024
Via
InvestorPlace
Takeda Named Global Top Employer for Seventh Consecutive Year
January 18, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Time to buy these 3 healthcare companies that raised revenue guidance?
January 16, 2024
Via
MarketBeat
U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
January 16, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.